<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091207</url>
  </required_header>
  <id_info>
    <org_study_id>2009-08-102</org_study_id>
    <nct_id>NCT01091207</nct_id>
  </id_info>
  <brief_title>Sorafenib for Imatinib/Sunitinib-failed GIST</brief_title>
  <official_title>A Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors Who Failed to Imatinib and Sunitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean GIST Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With discovery of KIT (CD117) mutations and the advent of KIT tyrosine kinase inhibitor&#xD;
      imatinib, there has been substantial improvement in overall survival in patients with&#xD;
      advanced and/or metastatic gastrointestinal tumors (GIST). Recently, sunitinib showed&#xD;
      activity as second-line therapy in GIST patients after failure with imatinib. However,&#xD;
      virtually all patients will eventually progress or become intolerable after imatinib and&#xD;
      sunitinib. In preclinical models, sorafenib inhibits KIT activity and cell growth of&#xD;
      imatinib-resistant tumors. The objective of this multi-center, non-randomized phase II study&#xD;
      is to evaluate the safety and activity of sorafenib given as third-line therapy for GIST.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, open-label, multi-center, phase II study recruiting patients with&#xD;
      advanced GIST who are pretreated with both imatinib and sunitinib. The current study will&#xD;
      provide an estimate of the activity and safety of sorafenib in GIST. The primary study&#xD;
      endpoint is the disease control rate (DCR), defined as complete or partial response or stable&#xD;
      disease of at least 24 weeks of sorafenib therapy. Secondary endpoints include PFS, OS and&#xD;
      safety.&#xD;
&#xD;
      Patients with advanced (unresectable and/or metastatic) GIST who failed after previous&#xD;
      therapy involving both imatinib and sunitinib will be eligible. Failure to imatinib and&#xD;
      sunitinib is defined as disease progression regardless of intervening response during&#xD;
      therapy, or intolerance. There is no limit to the number of prior therapies a patient may&#xD;
      have received (e.g., patients may have received therapy with nilotinib, other TKIs, or&#xD;
      chemotherapy in addition to imatinib or sunitinib).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-control rate</measure>
    <time_frame>Six months after registration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive daily oral administration of sorafenib 400 mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>The patients will receive daily oral administration of sorafenib 400 mg twice daily.</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age over 18 years&#xD;
&#xD;
          -  advanced GIST&#xD;
&#xD;
          -  failed (progressed and/or intolerable) after prior treatments for GIST&#xD;
&#xD;
          -  ECOG performance status of 0~2&#xD;
&#xD;
          -  resolution of all toxic effects of prior treatments&#xD;
&#xD;
          -  no prior radiotherapy within 1 month before registration&#xD;
&#xD;
          -  measurable lesion as defined by RECIST&#xD;
&#xD;
          -  adequate marrow, hepatic, renal and cardiac functions&#xD;
&#xD;
          -  provision of a signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe co-morbid illness and/or active infections&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  history of other malignancies&#xD;
&#xD;
          -  active CNS disease not controllable with radiotherapy or corticosteroids&#xD;
&#xD;
          -  active and uncontrollable bleeding from gastrointestinal tract&#xD;
&#xD;
          -  prior history of sorafenib use&#xD;
&#xD;
          -  gastrointestinal obstruction or malabsorption syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Se Hoon Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2010</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Se Hoon Park</name_title>
    <organization>Samsung Medical Center, Seoul, Korea</organization>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>GIST</keyword>
  <keyword>Refractory</keyword>
  <keyword>advanced GIST failed after both imatinib and sunitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

